<DOC>
	<DOCNO>NCT03058367</DOCNO>
	<brief_summary>This study evaluate benefit tolerability two dosage IQP-AE-103 ( 990mg 1980mg daily ) reduce body weight overweight moderately obese subject</brief_summary>
	<brief_title>Benefit Tolerability IQP-AE-103 Weight Loss</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<criteria>1 . Age 18 65 year 2 . Overweight moderately obese subject ( BMI ≥ 25 &lt; 35 kg/m2 ) 3 . Expressed desire weight loss 4 . Accustomed 3 main meals/day 5 . Commitment take IP recommend 6 . Commitment adhere diet recommendation study 7 . Commitment maintain habitual level activity/exercise study 8 . Consistent stable body weight 3 month prior V1 9 . Commitment avoid use weight management product program study 10 . Commitment ability complete subject diary study questionnaires 11 . Females childbearing potential : negative pregnancy test ( beta HCGtest urine ) V1 , agreement use appropriate contraception method study period 12 . Consents participate , understand requirement study willing comply 1 . Known sensitivity ingredient investigational product source ingredient 2 . Pregnancy nurse 3 . Smoking cessation within 6 month prior V1 study ( regular smoking study level prior study allow ) 4 . Current history abuse drug , alcohol medication 5 . Clinically relevant excursion safety laboratory parameter 6 . Diabetes mellitus type 1 7 . Untreated unstable diabetes mellitus type 2 8 . Untreated unstable endocrine disorder may influence body weight ( e.g . Cushing 's disease , thyroid gland disorder ) 9 . Stenosis gastrointestinal ( GI ) tract 10 . Bariatric surgery subject´s medical history 11 . Abdominal surgery within last 6 month prior V1 12 . Current use medication may affect body weight ( eg . antipsychotic , antidepressant , corticosteroid etc . ) 13 . Presence acute chronic gastrointestinal disease ( e.g . inflammatory bowel disease , coeliac disease , pancreatitis ) 14 . Digestion/absorption disorder gastrointestinal ( GI ) tract 15 . History eat disorder bulimia , anorexia nervosa within past 12 month prior V1 16 . Other serious organ systemic disease cancer within last 5 year prior V1 17 . Any electronic medical implant 18 . Use medication could influence GI function antibiotic within 4 week laxatives , opioids , glucocorticoid , anticholinergic within last 3 month prior V1 study , per investigator judgement 19 . Any medication use product treatment obesity ( e.g . orlistat , fat binder , carbohydrate/starch blocker , fat burner , satiety product etc . ) within last 3 month prior V1 study 20 . Participation similar study weight loss program within last 4 week prior V1 21 . Participation study last 4 week prior V1 22 . Inability comply 23 . Presence factor ( ) medication preclude subject participation per investigator judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>